% \begin{tabular}{@{}lll@{}}
% \toprule
% Stratification & Considerations & Examples of references \\
% \midrule
% \begin{tabular}[c]{@{}l@{}}Presence/severity\\of symptoms \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}Absent--Mild vs. Moderate--Severe \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}
%         \citet{cliff2019CellularImmune}
%     \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Groups/subgroups\\of specific symptoms \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}Identification of cluster\\from specific domains (Table~\ref{tab:intro-symptom-domains}) \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}
%         \citet{asprustenAreThereSubgroups2021};\\
%         \citet{malato2021Statisticalchallenges};\\
%         \textcolor{red}{Chapter}~\ref{}\\
%     \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Infection trigger/\\ viral infection \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}Link with (auto)immune dysregulations\\ (Unknown/No, Yes/Yes confirmed in laboratory)\end{tabular} & 
%         \begin{tabular}[c]{@{}l@{}}
%             \citet{domingues2021HerpesvirusesSerologya};\\ 
%             \citet{ruiz-pablos2021EpsteinBarrVirus};\\ 
%             \citet{sepulveda2022RevisitingIgG}
%         \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Duration of illness \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}Self-assessment of disease;\\Disease progression stage \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}
%         \citet{brenu2012LongitudinalInvestigation}
%     \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Illness onset \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}Gradual vs. sudden stage \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}. \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Age \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}. \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}
%     \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Comorbidities \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}Possible predispositions such as associated\\family diseases \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}\citet{lacerdaLogisticRegressionAnalysis2019}\end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Multiple phenomena \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}. \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}\citet{asprustenAreThereSubgroups2021} \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}Response to treatments \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}. \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}} \end{tabular} \\
%  & & \\
% \begin{tabular}[c]{@{}l@{}}. \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}. \end{tabular} & 
%     \begin{tabular}[c]{@{}l@{}}. \end{tabular} \\
% \bottomrule
% \end{tabular}
\begin{tabular}[c]{m{0.25\textwidth} m{0.5\textwidth} m{0.25\textwidth}}
\toprule
Stratification & Considerations & Examples of references \\
\midrule
\begin{tabular}[c]{@{}l@{}}Presence/severity\\of symptoms\end{tabular} & Compare subgroups for Absent vs. Present or Absent--Mild vs. Moderate--Severe & \begin{tabular}[c]{@{}l@{}}\citet{landay1991ChronicFatigue};\\ \citet{hardcastle2014AnalysisRelationship};\\
\citet{montoyaCytokineSignatureAssociated2017};\\
\citet{cliff2019CellularImmune}\end{tabular}\\
 & & \\
\begin{tabular}[c]{@{}l@{}}Subgroups of symptoms\end{tabular} & Identification of similar clusters within specific domains (Table~\ref{tab:intro-symptom-domains}) &
\begin{tabular}[c]{@{}l@{}}\citet{asprustenAreThereSubgroups2021};\\ Chapter~\ref{chapter:2024-sym-domains} \end{tabular}\\
 & & \\
\begin{tabular}[c]{@{}l@{}}Disease onset/trigger\end{tabular} & Link with (auto)immune dysregulations and production of autoantibodies; Unknown/No infection vs. Infection & 
\begin{tabular}[c]{@{}l@{}}\citet{szklarski2021DelineatingAssociationa};\\ \citet{domingues2021HerpesvirusesSerologya};\\ \citet{ruiz-pablos2021EpsteinBarrVirus};\\ \citet{sepulveda2022RevisitingIgG}\end{tabular}\\
& & \\
Disease duration & Linked with disease progression stages; Prodormal vs. Early vs. Established disease & \begin{tabular}[c]{@{}l@{}}\citet{brenu2012LongitudinalInvestigation};\\ \citet{stoothoffSubtypingPatientsMyalgic2017};\\ \citet{nacul2020HowMyalgic}\end{tabular} \\
& & \\
Age & Differences in severity of experienced symptoms & \begin{tabular}[c]{@{}l@{}}\citet{itoh2012FibromyalgiaChronic};\\ \citet{lewis2013ChronicFatigue};\\ \citet{miike2008ChronicFatigue}\end{tabular}\\
& & \\
Sex & Hormonal differences and possible predisposition towards the disease & \citep{pipper2023SexDisease} \\
% & & \\
% Comorbidities & Possible predispositions; linked with demographics and/or family history & \citet[Box~8]{nacul2021EuropeanNetwork} \\
% & & \\
% Treatments & Differences in response to treatments (clinical trials) or therapies & \citet{flugeBLymphocyteDepletionPatients2019} \\
% & & \\
% Multiple phenomena &  &  \\
% & & \\
\bottomrule
\end{tabular}
% \begin{tabular}[c]{@{}l@{}}  \end{tabular}


